Cancer Immunotherapy and Biomarkers

The paper shows MAGE-A4 promotes NSCLC by recruiting IgA+ plasma cells, reducing tumor burden and enhancing T cell activity.

This study shows that amyloid-β precursor protein (APP) promotes tumor growth by creating an immune-exclusive tumor microenvironment through suppression of CD8+ T cell and NK cell immunity.

The paper identifies hexa-acylated lipopolysaccharides from the gut microbiome as a biomarker and enhancer of anti-PD-1 immunotherapy responses in melanoma patients.

This study shows that zinc availability in the tumor microenvironment affects anti-PD1 therapy response in CDKN2A-low tumors through macrophage phagocytosis.

IMMUNOTAR prioritizes and identifies immunotherapeutic targets by integrating RNA-sequencing and proteomics data with public databases to evaluate surface proteins across diverse criteria.

This study shows that LIMD1 loss in lung cancer increases PD-L1 expression, promoting immune evasion and enhancing response to immune checkpoint inhibitors.

This study shows hypoxia alters T cell transcriptomes in melanoma, correlating with poor clinical outcomes in non-responders to immunotherapy.

This study shows that neoadjuvant anti-4-1BB therapy reduces metastasis by enhancing Tint cell clonal expansion and T cell egress in TNBC.

This study shows that chronic antigen exposure leads to T cell exhaustion, reducing the effectiveness of T cell bispecific therapies in solid tumors.

This study uses whole-slide digital analysis of multiplexed immunofluorescence images to quantify TLS immune activity in CRC, showing it is more efficient and reveals strong correlations between B-cell and T-cell proliferation.

The paper uses spatial imaging and computational analysis to identify features in metastatic tumors that predict response to immune checkpoint inhibition in TNBC patients.

This study shows that timing anti-PD-L1 therapy after radiation enhances tumor response by preventing CTL depletion and improving PD-L1 blockade.

ImmunoVerse integrates RNA-Seq and immunopeptidomes to catalog 28,446 tumor-specific HLA-presented antigens across 21 cancers, including a splicing-derived PMEL peptide with T cell expansion support.

This study identifies PD-1's role in regulating effector potential and exhaustion in thymic CD8+ T cells, showing that PD-1 inhibition enhances expansion but leads to exhaustion in tumor tissues.

This study investigates the evolutionary timing of immune escape mutations across 38 cancer types using functional genomics and tumor evolution reconstruction.

This study analyzes immune cell dynamics in HPV-negative HNSCC using single-cell RNA sequencing to identify molecular signatures and communication patterns associated with disease progression.

The paper develops a method combining multiplexed imaging and proteomics to analyze tumor microenvironments, identifying immune cell interactions and adaptations in colorectal and tonsil cancers.

This study compares immunotherapy responses in subcutaneous and orthotopic dMMR LUAD models, finding that orthotopic models show better anti-PD1 response with increased immune infiltration and CD4+ memory T cells.

This study develops a 37-marker spectral flow cytometry assay for high-dimensional immunophenotyping of cryopreserved liquid biopsies and validates its robustness against cryopreservation effects.

The paper assesses T-cell dynamics in pediatric cancer patients during treatment, finding that immune checkpoint proteins and T-cell subsets change with therapy, and introduces a Dynamic Immunogenomic Score to predict relapse risk.

This study identifies a four amino acid motif in VISTA that suppresses tumor growth by altering EGFR signaling through NUMB recruitment.

This study compares human and rodent PD1 proteins, finding rodent PD1 has weaker inhibitory activity and stronger tumor immunity due to evolutionary changes in Shp2 recruitment.

The paper shows that IFN-gamma-insensitive tumours can still be controlled by immune responses, with IFN-gamma driving myeloid cell remodelling that enhances anti-tumour immunity.

This study evaluates TMB cutoffs for predicting immunotherapy outcomes across multiple cancer types and endpoints, finding replicable associations for specific cutoffs in melanoma, lung, and bladder cancers.

This study shows that combining immunotherapies can lead to divergent tumor responses based on the tumor microenvironment, with Treg depletion reversing progression in pancreatic cancer.

This paper shows that combining PARP14 inhibition with PD-1 blockade enhances immune responses in melanoma by promoting T cell quiescence and modulating macrophage polarization.

This study identifies immune suppressive barriers in preinvasive lung cancer progression using single-cell analyses, revealing key cellular and spatial changes that could inform therapeutic strategies.

This paper shows that immune checkpoint blockade (ICB) can delay cancer onset and improve survival in mice with mutator syndromes, but only if administered prophylactically before tumors develop.

The paper generates and characterizes primary human cytotoxic T cells with suppressed function in vitro, showing their resemblance to exhausted tumor-infiltrating CTL and identifying factors affecting their effector function.

The paper shows antimitotic chemotherapy induces a NF-kB secretory phenotype in triple-negative breast cancer, promoting immunosuppressive CXCR2+ neutrophil chemotaxis, and demonstrates that CXCR2 inhibition enhances antitumor immunity.